Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, non-interventional, open-label study investigating the effect of glatiramer acetate in patients with relapsing-remitting multiple sclerosis

Next Previous
Trial Profile

A multicenter, non-interventional, open-label study investigating the effect of glatiramer acetate in patients with relapsing-remitting multiple sclerosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms COPTIVITY

Most Recent Events

  • 12 Oct 2018 Interim results (n=744) assessing safety and efficacy of new formulation of GA40mg, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
  • 19 Jun 2018 Interim results presented at the 4th Congress of the European Academy of Neurology
  • 27 Jun 2017 Results from COPTIVITY and QualiCOP studies presented at the 3rd Congress of the European Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top